Is NMN Banned? US, EU, UK & Australia Status Explained

Is NMN banned in 2026? In the United States, no: NMN is not currently excluded from the dietary-supplement definition under FDA's drug-preclusion interpretation. FDA changed its earlier position on September 29, 2025. That does not mean NMN is “FDA approved,” and it does not make every NMN product automatically compliant.

Outside the United States, the answer is different. In the European Union, NMN is treated as a novel food and a favorable 2026 EFSA safety opinion for one specified β-NMN material is not the same as final market authorization. In Great Britain, an EffePharm β-NMN novel-food application remains in risk assessment as of September 2026.

NMN regulatory status at a glance

Market	Status as of September 19, 2026	What that means
United States	FDA no longer treats NMN as excluded from the dietary-supplement definition under the drug-preclusion clause	NMN can proceed through the normal supplement framework, subject to ingredient, manufacturing, labeling and claims rules
European Union	NMN is a novel food; applications are ongoing	A favorable EFSA safety opinion does not itself place NMN on the Union list of authorized novel foods
Great Britain	β-NMN application RP-2116 remains in risk assessment	Risk assessment is not final authorization

Why people still ask whether NMN is banned

The confusion comes from FDA's 2022 position. At that time, the agency concluded that NMN was excluded from the dietary-supplement definition because it had been authorized for investigation as a new drug before qualifying supplement marketing.

That position had real commercial consequences. Major marketplaces removed NMN products, brands changed distribution plans, and “NMN banned” became a durable search result—even after the regulatory picture changed.

What changed on September 29, 2025?

FDA responded to citizen petitions and revised its application of the drug-preclusion rule to NMN. Industry organizations reporting the agency's response state that FDA concluded NMN is not excluded from the dietary-supplement definition under section 201(ff)(3)(B) because evidence showed NMN had been marketed as a dietary supplement in the United States before the relevant drug-investigation threshold.

The Council for Responsible Nutrition and the Natural Products Association both published the September 29, 2025 outcome.

Does “NMN 18000 FDA” mean an 18,000 mg product is FDA approved?

No. Search phrases such as “NMN 18000 FDA” combine a product-style bottle quantity with a regulatory question. “18,000” generally refers to total labeled NMN across the bottle, not an FDA designation, approved dose or safety threshold.

FDA's current NMN position concerns whether NMN is excluded from the dietary-supplement definition under the drug-preclusion provision and the ordinary supplement/NDI framework. It does not approve a product because its name contains 9000, 12000, 18000 or another large number.

Does that mean NMN is FDA approved?

No. This is one of the most important distinctions on the page.

• FDA approval is the premarket drug-approval concept consumers usually have in mind.
• Dietary-supplement eligibility means an ingredient can potentially be marketed within the supplement framework if the applicable requirements are met.
• New dietary ingredient notification is a separate process focused on ingredient identity and safety under proposed conditions of use.

None of these allows a supplement company to claim that NMN is FDA-approved to reverse aging, treat diabetes, prevent cancer or cure another disease.

What is NDI 1444?

FDA's public list of submitted new dietary ingredient notifications records NDI 1444 for beta-nicotinamide mononucleotide (β-NMN), submitted by EffePharm on November 17, 2025, with a listed response date of January 28, 2026.

You can verify that entry directly in FDA's Submitted 75-Day Premarket Notifications for New Dietary Ingredients.

The existence of an NDI notification should not be rewritten as “FDA approved NMN.” It is regulatory documentation, not approval of efficacy.

What requirements still apply in the United States?

The 2025 reversal resolved the specific drug-preclusion problem; it did not erase the rest of supplement law. A finished product can still have compliance problems involving:

• ingredient identity or applicable NDI obligations;
• adulteration or contamination;
• current good manufacturing practice;
• misbranding or inaccurate Supplement Facts;
• unsupported structure/function claims; or
• unapproved disease-treatment claims.

“NMN is allowed as a supplement ingredient” and “this bottle is compliant and well made” are two different statements.

Can NMN companies say it treats disease?

No. A supplement cannot lawfully turn its regulatory status into an unapproved disease claim. Language such as “treats diabetes,” “prevents Alzheimer's disease,” “cures hypertension” or “treats cancer” would raise a very different regulatory issue from ordinary supplement marketing.

That distinction also matters editorially: human NMN evidence is mixed even before the legal claims standard is considered.

Why Amazon's policy is not the same as FDA status

Retailers create their own listing and compliance policies. They can remove a product category before an agency reaches a final position, require extra documentation, or take time to change policy after a regulatory update.

So “Amazon removed NMN” was never identical to “Congress banned NMN,” and marketplace availability today is not proof that a product meets every regulatory requirement.

What is NMN's status in the European Union?

The European Commission's novel-food consultation process lists nicotinamide mononucleotide as a novel food. Under EU rules, a novel food cannot simply be placed on the market because a safety paper looks favorable; authorization requires the Commission process and inclusion in the Union list.

EFSA published a 2026 scientific opinion concluding that a specified chemically synthesized β-NMN material was safe under proposed conditions up to 300 mg/day for adults excluding pregnant and lactating women. ^[1]

That is an important safety assessment. It is not a blanket authorization of all NMN products, manufacturing routes or doses.

Has NMN been authorized on the EU Union list?

As of this page's September 19, 2026 verification, the European Commission continues to list β-NMN applications in its novel-food application system, while the current Union-list update does not show a general β-NMN authorization.

The practical editorial rule is therefore: do not write “EFSA approved NMN for Europe.” EFSA performs scientific risk assessment; European Commission authorization is the separate market-access step.

What is NMN's status in Australia?

Australia now permits NMN in listed medicines under defined conditions. The TGA states that NMN was added to the Therapeutic Goods (Permissible Ingredients) Determination effective December 10, 2025.

• NMN must be used as an active ingredient.
• The route must be oral.
• The maximum recommended daily dose must not exceed 500 mg.
• The recommended duration must be 12 weeks or less.
• Products are for adults only and not pregnant or lactating women.
• Additional sponsor-authorization conditions apply through December 10, 2027.

The TGA also warns that NMN products or advertising outside the ARTG framework may breach Australian therapeutic-goods law. Several NMN products were added to the ARTG in 2026. An AUST L listing is not equivalent to premarket proof that NMN reverses aging or improves longevity.

What about the United Kingdom?

Great Britain has its own regulated-product process after Brexit. The UK Food Standards Agency currently lists RP-2116, β-Nicotinamide Mononucleotide, submitted by EffePharm, as in progress and in the risk-assessment phase.

See the current FSA application record. A pending risk assessment should not be described as UK authorization.

Why the exact NMN material matters

Novel-food and NDI assessments are tied to a defined material: manufacturing process, specifications, contaminants, stability and proposed conditions of use. A favorable assessment or notification history for one β-NMN source does not automatically validate every unrelated powder sold online.

This is where regulation and product-quality verification meet. See how to evaluate NMN COAs, identity and potency.

What should consumers take from the regulatory story?

• The old one-line claim “FDA banned NMN” is outdated for the United States.
• “FDA approved NMN” is also wrong.
• NDI documentation is not efficacy approval.
• EU and UK rules are separate from U.S. supplement law.
• EFSA safety assessment is not the same as European Commission authorization.
• Regulatory eligibility does not prove a product contains the labeled amount of β-NMN.

How we keep this page current

This article is verified to September 19, 2026. NMN has already changed regulatory status materially within a few years, so this page should be rechecked whenever FDA publishes a new petition response or NDI letter, the European Commission updates the Union list, or the UK FSA advances RP-2116.

Related NMN guides

• NMN purity and regulatory documentation
• Uthever NMN evidence and regulatory history
• NMN products compared
• NMN supplement guide
• where to buy NMN by country and retailer

Bottom line

NMN is not currently excluded from the U.S. dietary-supplement definition under FDA's drug-preclusion interpretation, but it is not “FDA approved.” Europe and Great Britain remain separate novel-food questions: EFSA has issued a favorable safety assessment for a specified β-NMN material, while EU authorization and the UK risk-assessment process should not be overstated.